| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1499 | 2020 |
| Patient-derived organoids model treatment response of metastatic gastrointestinal cancers G Vlachogiannis, S Hedayat, A Vatsiou, Y Jamin, J Fernández-Mateos, ... Science 359 (6378), 920-926, 2018 | 1475 | 2018 |
| Whole-genome landscape of pancreatic neuroendocrine tumours A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ... Nature 543 (7643), 65-71, 2017 | 837 | 2017 |
| Micro-RNA profiling in kidney and bladder cancers F Gottardo, CG Liu, M Ferracin, GA Calin, M Fassan, P Bassi, C Sevignani, ... Urologic Oncology: Seminars and Original Investigations 25 (5), 387-392, 2007 | 784 | 2007 |
| Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas Y Jiao, TM Pawlik, RA Anders, FM Selaru, MM Streppel, DJ Lucas, ... Nature genetics 45 (12), 1470-1473, 2013 | 688 | 2013 |
| MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets R Baffa, M Fassan, S Volinia, B O'Hara, CG Liu, JP Palazzo, M Gardiman, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2009 | 622 | 2009 |
| Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial EC Smyth, A Wotherspoon, C Peckitt, D Gonzalez, S Hulkki-Wilson, ... JAMA oncology 3 (9), 1197-1203, 2017 | 489 | 2017 |
| Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas E Amato, M Molin, A Mafficini, J Yu, G Malleo, B Rusev, M Fassan, ... The Journal of pathology 233 (3), 217-227, 2014 | 347 | 2014 |
| Gastritis OLGA‐staging and gastric cancer risk: a twelve‐year clinico‐pathological follow‐up study M Rugge, M de Boni, G Pennelli, M de Bona, L Giacomelli, M Fassan, ... Alimentary pharmacology & therapeutics 31 (10), 1104-1111, 2010 | 347 | 2010 |
| DNA qualification workflow for next generation sequencing of histopathological samples M Simbolo, M Gottardi, V Corbo, M Fassan, A Mafficini, G Malpeli, ... PloS one 8 (6), e62692, 2013 | 326 | 2013 |
| MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer N Valeri, C Braconi, P Gasparini, C Murgia, A Lampis, V Paulus-Hock, ... Cancer cell 25 (4), 469-483, 2014 | 322 | 2014 |
| Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations CP Wardell, M Fujita, T Yamada, M Simbolo, M Fassan, R Karlic, P Polak, ... Journal of hepatology 68 (5), 959-969, 2018 | 308 | 2018 |
| Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 F Zanconato, G Battilana, M Forcato, L Filippi, L Azzolin, A Manfrin, ... Nature medicine 24 (10), 1599-1610, 2018 | 264 | 2018 |
| Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial EC Smyth, M Fassan, D Cunningham, WH Allum, AFC Okines, A Lampis, ... Journal of Clinical Oncology 34 (23), 2721, 2016 | 264 | 2016 |
| The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ L Chang, L Azzolin, D Di Biagio, F Zanconato, G Battilana, ... Nature 563 (7730), 265-269, 2018 | 259 | 2018 |
| Gastritis: the histology report M Rugge, G Pennelli, E Pilozzi, M Fassan, G Ingravallo, VM Russo, ... Digestive and Liver Disease 43, S373-S384, 2011 | 237 | 2011 |
| Gastric cancer as preventable disease M Rugge, RM Genta, F Di Mario, EM El-Omar, HB El-Serag, M Fassan, ... Clinical Gastroenterology and Hepatology 15 (12), 1833-1843, 2017 | 223 | 2017 |
| Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation P Gasparini, F Lovat, M Fassan, L Casadei, L Cascione, NK Jacob, ... Proceedings of the National Academy of Sciences 111 (12), 4536-4541, 2014 | 218 | 2014 |
| Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial KH Khan, D Cunningham, B Werner, G Vlachogiannis, I Spiteri, T Heide, ... Cancer discovery 8 (10), 1270-1285, 2018 | 209 | 2018 |
| Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ... Oncotarget 5 (9), 2839, 2014 | 209 | 2014 |
Massimo RuggeUniversità di PadovaVerified email at unipd.it
